AGL

agilon health, inc. (AGL) SWOT Analysis Analysis (2026)

Invetso Score: 3.6/10 — Weak · Last Updated: 2026-08-01

Overall Score

Strengths

Very low valuation on sales and cash flow, with EV/Sales at 0.24x and price-to-sales at 0.25x.

Balance sheet leverage appears manageable, with net debt to EBITDA at 0.32x and a current ratio of 1.08x.

Asset turnover is strong at 3.72x, indicating efficient use of the asset base.

Weaknesses

Profitability remains deeply negative, with net margin at -4.2%, EBIT margin at -4.4%, and ROE at -119.3%.

Cash generation is weak, with operating cash flow negative and free cash flow yield at -6.7%.

Interest coverage is extremely poor at -79.1x, highlighting significant earnings pressure.

Opportunities

A low valuation could offer upside if margins and cash flow normalize.

Improving working capital efficiency could help support liquidity, given a cash conversion cycle of 48.4 days.

If operating losses narrow, the current low EV/Sales multiple could re-rate higher.

Threats

Persistent losses and negative cash flow increase the risk of dilution or financing needs.

Weak interest coverage raises refinancing and covenant risk if operating performance does not improve.

The company’s profitability metrics remain far below breakeven, leaving little margin for error.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on agilon health, inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →